health

Vetoquinol: after a mixed year, the outlook is improving

The animal health specialist suffered in 2022, but the accounts and the new strategic plan were well received. Vetoquinol’s annual turnover was 5% below consensus expectations at 521 million euros, down 0.8% organically, slowed down by a third and final quarter with respective declines of 4.5 and 2.4%, causing the stock to fall. The publication

Vetoquinol: after a mixed year, the outlook is improving Read More »

Action advice – Virbac: the market relieved by the good performance of sales

The veterinary laboratory reported half-yearly activity slightly better than anticipated. On the stock market, the title benefits. While the clouds were accumulating over the animal health specialist, and its stock was suffering, the publication of the half-yearly turnover gave the price some breathing room. Indeed, while Virbac revised its annual targets sharply downward at the

Action advice – Virbac: the market relieved by the good performance of sales Read More »

Action advice – Vetoquinol: a first half more difficult than expected

The group did not escape the gloom in the animal health sector in the first half of 2023. A recovery is expected, but the profitable growth targeted for the year is fading. The Vetoquinol stock has never really recovered from the drop suffered a year ago, after the publication of disappointing 2022 half-year accounts. While

Action advice – Vetoquinol: a first half more difficult than expected Read More »

The veterinary laboratory accelerated over the last financial year

The strategic refocusing of the animal health specialist on its most promising niches is a success, as evidenced by the annual accounts. Vetoquinol had already revealed an annual turnover of 521 million euros, gross growth of 21.9% including 13.7% organic. The difference between the two progressions is mainly explained by the integration of Drontal and

The veterinary laboratory accelerated over the last financial year Read More »

A much better dynamic than expected at the start of the financial year

A much better dynamic than expected at the start of the financial year The veterinary laboratory, despite a basis of comparison which has become high, published quarterly activity in very strong growth. On the stock market, the trend was less positive for Virbac shares since January 1, but the latest publication is now widely welcomed.

A much better dynamic than expected at the start of the financial year Read More »

The normalization of growth is happening at a forced march

The veterinary laboratory is suffering from the downturn in the animal health market as evidenced by its quarterly activity, which was in organic decline. Investors finally welcomed the publication of Vetoquinol’s third quarter sales, with the stock increasing by almost 6% in the session that followed it. The market was clearly anticipating a more marked

The normalization of growth is happening at a forced march Read More »

Scroll to Top